Novelion Therapeutics Inc. (NASDAQ:NVLN)
Novelion Therapeutics Inc. (NASDAQ:NVLN) represented a move of -1.54 percent or $-0.04 per share and closed its previous day trading session at $1.28. 1.38 Million Shares were traded in the last trading session with an Average Volume of 2.18 Million Shares. The stock currently has a Market Capitalization of 23.14 Million.
Novelion Therapeutics is a biopharmaceutical company. It engages in developing and marketing of ocular products for individuals living with rare diseases. The product portfolio includes MYALEPT(R) and JUXTAPID (R) and is also developing zuretinol and metrleptin. Novelion Therapeutics formerly known as QLT Inc. is headquatered in Vancouver, Canada.
The stock traded between $0.70 and $5.87 over 1-Year time period showing its price to sales ratio of 0.18. Novelion Therapeutics Inc. (NASDAQ:NVLN) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-3.25 and 200-Day Simple Moving Average of $-60.41. Its Price to Free Cash Flow is 0 and Price to Book of 0.
Analyst’s recommended the stock as 3 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Novelion Therapeutics Inc. (NASDAQ:NVLN) reported its Actual EPS of $-1.32/share. The analysts offering Earnings Estimates for the company were believing that Novelion Therapeutics Inc. could bring EPS of $-1.49/share. The difference between Actual EPS and Estimated EPS was 0.17 Percent. Thus showing an Earnings Surprise of 11.4 Percent.
Histogenics Corporation (NASDAQ:HSGX)
In the last trading session, Histogenics Corporation (NASDAQ:HSGX) added its value by 0.71% closing at the price of $0.42. The stock currently has market capitalization of 29.25 Million, with average volume of 5.17 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Histogenics Corporation (NASDAQ:HSGX) is showing beta of 1. This particular value of beta suggests that Histogenics Corporation (NASDAQ:HSGX) has historically moved 100% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Histogenics Corporation (NASDAQ:HSGX) is at $-0.43.
The stock currently has RSI of 39.66. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts.
Histogenics Corporation (NASDAQ:HSGX) topped its 52-week high price of $3.350 on 03/15/18 and 52-Week Low Price of $0.380 on 11/15/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 8.65% and monthly volatility of 11.70% respectively.